Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study
F1000Research · 2024
DOI: 10.12688/f1000research.152196.1 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift F1000Research, 2024. Verfasst von Hela Cherif und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, Internal Security Forces Hospital, Tunis, Tunisia. Hauptthemen laut MEDLINE: COVID-19, Hyperventilation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study investigates the incidence and predictive factors of Hyperventilation Syndrome (HVS) in patients after COVID 19 pneumonia, addressing the clinical overlap between these conditions.
Methods
A one-month prospective study was conducted, tracking survivors of COVID-19 pneumonia. Patients were evaluated for ongoing clinical status, including HVS and post-traumatic syndrome disorder (PTSD), using clinical questionnaires, mMRC, Post-COVID-19 Functional Status (PCFS) Score, Nijmegen score, and PTSD Checklist for DSM-5 questionnaire.
Results
Our study included 222 patients (median age: 57 years, male predominance 62.6%). Somatic comorbidities, primarily metabolic disorders, were reported in 71.2% of cases. The majority had severe or critical infection forms (78.4%), and 91.9% experienced acute symptoms, with 86.5% having three or more symptom clusters. At one month follow-up, dyspnea (52.9%) and asthenia (21.7%) persisted. Functional limitations (PCFS Grade > 2) were observed in 19.6% of patients. The overall incidence of HVS was 158 per 1000 patients, and PTSD was 445 per 1000 patients. Multivariate logistic regression identified cognitive impairment (acute phase), persistent weight loss (post-COVID-19 phase), PCFS grade > 2, and PTSD as independent factors for developing HVS, with relative risks (RRs) of 3.47 (95%CI [1.48-8.31]; p = 0.004), 11.87 (95%CI [1.25-112.88]; p = 0.031), 3.24 (95%CI [1.34-7.86]; p = 0.009), and 5.98 (95%CI [2.27-15.77]; p < 0.001), respectively.
Conclusion
HVS is prevalent in the post-COVID-19 phase, affecting 15.6 % of survivors. Identified predictive factors suggest the convergence of psychosomatic pathophysiological mechanisms. Further research is crucial for a detailed understanding of these mechanisms in long COVID-19 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pulmonology Department, Internal Security Forces Hospital, Tunis, Tunisia.
- Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunis, Tunisia.
- Research Laboratory on Health and Environment for security Foces LR21INT01, Tunis, Tunisia.
ORCID-Profile: Hela Cherif, Salma Mokaddem, Soumaya Debiche, Ferdaous Yangui
Zitieren
APA
Cherif, H., Mokaddem, S., Debiche, S., Kalboussi, S., Yangui, F., & Charfi, M. R. (2024). Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study. F1000Research. https://doi.org/10.12688/f1000research.152196.1
Vancouver
Cherif H, Mokaddem S, Debiche S, Kalboussi S, Yangui F, Charfi MR. Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study. F1000Research. 2024. doi:10.12688/f1000research.152196.1
BibTeX
@article{Cherif2024,
author = {Cherif, Hela and Mokaddem, Salma and Debiche, Soumaya and Kalboussi, Slim and Yangui, Ferdaous and Charfi, Mohamed Ridha},
title = {Incidence and predictive factors of hyperventilation syndrome in patients after COVID 19 pneumonia: a prospective cohort study},
journal = {F1000Research},
year = {2024},
doi = {10.12688/f1000research.152196.1}
}
EUVIMED